Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387309 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus
A Phase 3 study of Post Operative Bowel Dysfunction, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 495
- Enrollment target
- 20
- Study locations
NCT00387309: Completed Phase 3 study of Post Operative Bowel Dysfunction, sponsored by Bausch Health Americas.
NCT00387309 is a Phase 3 study of Post Operative Bowel Dysfunction that has completed, run by Bausch Health Americas. The registered enrollment target is 495 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00387309, a Phase 3 study of Post Operative Bowel Dysfunction, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 495 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Objective: In subjects who have undergone segmental colectomy, the time between the end of surgery and first bowel movement is significantly shorter with the investigational MOA-728 regimen than with a placebo regimen.
Conditions Studied
Interventions
- DRUG Methylnaltrexone (MOA-728)
Study Locations (20)
California
- - Chula Vista
- - Colton
- - Los Angeles
- - Oceanside
- - Palo Alto
- - San Jose
- - Torrance
Florida
- - Bay Minette
- - Jacksonville
- - Melbourne
- - Naples
- - St. Petersburg
- - Vero Beach
- - Weston
Georgia
- - Atlanta
- - Atlanta
Alabama
- - Mobile
Arkansas
- - Fort Smith
Colorado
- - Denver
District of Columbia
- - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 495 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
What the finished NCT00387309 record still lists
NCT00387309 is an interventional study that assigns participants to a tested intervention. The registered 495 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Post Operative Bowel Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which Methylnaltrexone (MOA-728) is the first listed.
NCT00387309 names 20 study sites across 7 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00387309 about?
NCT00387309 is a clinical study titled "Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus". Primary Objective: In subjects who have undergone segmental colectomy, the time between the end of surgery and first bowel movement is significantly shorter with the investigational MOA-728 regimen than with a placebo regimen.
What is the current status of trial NCT00387309?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 495 participants. The study started on 2006-12. Estimated completion is 2007-11.
What conditions does trial NCT00387309 study?
This clinical trial studies the following conditions: Post Operative Bowel Dysfunction.
What interventions are being tested in trial NCT00387309?
The interventions under investigation include: Methylnaltrexone (MOA-728) (DRUG).
Who is sponsoring clinical trial NCT00387309?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00387309 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00387309's enrollment target sits among peer trials
495 778th of 2000 higher than 1,222 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03127267 · 495 participants · Phase 3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
- NCT06400472 · 495 participants · Phase 1
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia